1207344-05-5
Chemical Structure
(R)-Oxybutynin hydrochloride
Synonym(s): Aroxybutynin hydrochloride
- CAS No.: 1207344-05-5
- Formula:C22H32ClNO3
- Molecular Weight:393.95
IUPAC Name: 4-(diethylamino)but-2-yn-1-yl (R)-2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride
InChIKey: SWIJYDAEGSIQPZ-FTBISJDPSA-N
SMILES: O=C([C@](C1=CC=CC=C1)(C2CCCCC2)O)OCC#CCN(CC)CC.Cl
Biological Activity: (R)-Oxybutynin hydrochloride (Aroxybutynin hydrochloride), an enantiomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Oxybutynin hydrochloride | 98.08% | (R)-Oxybutynin hydrochloride (Aroxybutynin hydrochloride), an enantiomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oxybutynin-d5 hydrochloride | Oxybutynin-d5 hydrochloride is the d5-labeled (R)-Oxybutynin hydrochloride (HY-B0267B). (R)-Oxybutynin hydrochloride (Aroxybutynin hydrochloride), an enantiomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride exhibits antispasmodic and anticholinergic activities, and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used in the research of urinary incontinence caused by neurogenic bladder dysfunction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Smith ER, et al. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Arzneimittel-Forschung. 1998 Oct;48(10):1012-8. [Content Brief]
- [2]. Zobrist RH, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmaceutical research. 2001 Jul;18(7):1029-34. [Content Brief]
- [3]. Horner RL, et al. Mechanisms of upper airway muscle control in sleep reveal therapeutic targets for obstructive sleep apnea. American journal of respiratory cell and molecular biology. 2026 Jul 01;74(7):847-857.
- [4]. Siddiqui MA, et al. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64(8):885-912. [Content Brief]
